CRP and coronary artery disorder: Colchicine (0.5 mg) daily treatment resulted in 31% lower relative risk of CVD endpoint compared with placebo with median 28.6 months follow-up and reduced risk of atherosclerotic cardiovascular disease (ASCVD) by 23% compared with placebo and in coronary artery disease (CAD) patients; CRP levels were not measured in this trial [67].